



## Angel Investor Tax Credit Program Deadline

Applications for the New Jersey Angel Investor Tax Credit Program must be submitted by **11:59 p.m. on November 1** to be considered for the 2021 program year. Applications received after this time will be considered for the 2022 program year. Through the Angel Investor Tax Credit Program, an investor can receive a refundable tax credit equal to 20%, or more, of their qualified investment made in a New Jersey early-stage company. [Learn more](#)

## Availability at the New Jersey Bioscience Center Research Park

The Incubator has two large labs and one small lab available now. More small labs will be available in a few months. [Email](#) or call Lenzie with any questions.

## In The News

### [Adlai Nortye Raises \\$100M D Round](#)

Step-Out Labs resident, Adlai Nortye, a clinical-stage biopharmaceutical company focused in oncology, raised nearly US \$100 million in a series D round financing in July. In addition to advancing its pipeline and furthering R&D, Adlai Nortye said some of the funds could be used for “mergers and acquisitions and other strategic collaborations”.

### [Oyster Point Pharma Announces FDA Approval](#)

Step-Out Labs resident, Oyster Point Pharma (NASDAQ OYST) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies to treat ocular surface diseases. The company recently announced that the FDA granted approval for TYRVAYA (varenicline solution) Nasal Spray 0.03 mg for the treatment of the signs and symptoms of dry eye disease. TYRVAYA Nasal Spray is the first and only nasal spray approved for the treatment of dry eye disease.

Oyster Point Pharma also recently announced preclinical data in non-human primates and in vitro models evaluating OC-01 (varenicline) nasal spray against SARS-CoV-2 and the alpha and beta variants, the viruses that cause COVID-19 disease.

### [2021 Best Contract Research Provider](#)

Former Incubator resident, NJ BIO, a CRO providing integrated chemistry and biology services, was recently awarded Best Contract Research Provider at the 2021 World ADC Awards.

### [Ascendia Pharmaceuticals on the 2021 Inc. 5000 List](#)

Congratulations to Ascendia Pharma for rising nearly 3,300 spots to #1,422 on the Inc. 5000 List of America's Fastest-Growing Private Companies! The current NJ Bioscience Center resident and graduate of the Incubator at North Brunswick achieved 333% growth over the past three years.

### [BioAegis Therapeutics Awarded BARDA Contract](#)

BioAegis announced in June that it had been awarded a contract from Biomedical Advanced Research and Development Authority (BARDA), to further develop the company's novel host-directed therapy for the critically ill sepsis patient population. BioAegis offers a novel recombinant protein therapy with the potential to broadly treat inflammatory disorders, like sepsis, that can arise from injury or infection. BioAegis is a current resident of the Step-Out Labs and a graduate of the Bioscience Center Incubator.

### [PDS Biotech Announces PHASE 2 Study](#)

[PDS Biotechnology Corporation](#) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines, recently announced its VERSATILE-002 Phase 2 study for the treatment of advanced human papillomavirus (HPV16)-associated head and neck cancer achieved its preliminary safety benchmark in its first 12 patients. PDS is a former resident of the Bioscience Center Incubator. [Learn more](#)

### [First IVF Baby, Now 39, Joins The Genomic Prediction Team](#)

Elizabeth Carr was the first baby born via in vitro fertilization in the United States. In the media since 3 cells old, Elizabeth is a passionate advocate for those fighting for fertility rights. Elizabeth is a marathoner, triathlete, coffee connoisseur, wife, mother, and writer. She also recently joined the [Genomic Prediction team](#) as a Patient Advocate, striving to educate, help, and empower patients based on her life experiences within the fertility world. Genomic Prediction is a soon-to-be-graduate of the Incubator at North Brunswick.





## New Jersey Innovation & Technology HUB Ground-breaking

On October 14<sup>th</sup>, 2021 the groundbreaking occurred for the **New Jersey Innovation and Technology HUB**, a 550,000 square foot development that will be a center of innovation, research and medical education in downtown New Brunswick. The project represents a \$665 million investment in the areas of innovation, translational research, and medical education.

[Learn more](#)

## In The News

### [Aucta Grows to 45 Employees; Launches New Product](#)

Aucta Pharmaceuticals, a graduate of the Incubator at North Brunswick, is a development company focusing on branded 505b2 new product development. Aucta recently announced the U.S. launch of a generic version of JADENU® Sprinkle (Deferasirox Granules). "We are excited to bring another Aucta Pharmaceuticals developed product to the U.S. market through this partnership with Oakrum Pharma. Aucta Pharmaceuticals continues to expand its product portfolio in niche generics and branded specialty products and is anticipating additional approvals and launches in the next 12 months."

## Life Sciences Real Estate News in New Jersey

### [Princeton West Innovation Campus Announcements](#)

On October 14<sup>th</sup>, PTC Therapeutics cut the ribbon on its [new gene therapy manufacturing facility](#). Located at the Princeton West Innovation Campus in Princeton, PTC's new site is approximately 220,500 square feet of office, manufacturing and laboratory space, including state-of-the-art technology equipped to handle process development and manufacturing of plasmids and adeno-associated virus (AAV) vectors.

In August, BeiGene, Ltd, focused in oncology, announced its plans to build a new R&D and manufacturing site at the Princeton West Innovation Campus. [BeiGene goal is to acquire](#) approximately 42-acres with over 1 million square feet of real estate, to build a state-of-the-art facility.

Princeton West Innovation Campus is a multi-tenant research park on a 433 acre former BMS site with over 30 buildings.

### [Quest Diagnostics unveils its largest testing lab at the ON3 Campus](#)

On October 12, [Quest Diagnostics](#) completed the consolidations of its Northeast regional operations into its new, 250,000-square-foot facility at ON3 Campus. Spread over 116 acres with over 1 M square feet, the ON3 research park is the former Roche site. The Quest lab represents a \$250 million commitment, Quest said, and will employ more than 1,000 people.

### [SciTech Scity Innovation Campus Breaks Ground](#)

Also in October, Liberty Science Center's transformational "City of Tomorrow" took a step closer to reality as the 30-acre innovation campus held a ground breaking. The site's goal is to launch and grow world-changing science and technology companies and reimagine public school science education.

### [95 Greene Announces First Tenant - RWJBH](#)

In October, the new 335,000 square foot life sciences property in Jersey City near the Hudson River, 95 Greene, announced its first tenant as RWJBarnabas Health and its Jersey City Medical Center. RWJBH signed for 11,235 square feet of ground-floor retail space with a dedicated entrance.



NEW JERSEY  
**BIOSCIENCE CENTER**  
INCUBATOR AND STEP-OUT LABS  
AT NORTH BRUNSWICK

